Latest news

• Vectura to merge with SkyePharma in £441m deal

  Vectura recorded revenues of £26m in the six-month period ended September 2015 - up 35% - as royalties increased on products such as Novartis' Ultibro Breezhaler (indacaterol/glycopyrronium bromide).

• Novartis sets sights on connected inhaler

  The next-generation Breezhaler falls within the pharma firm's collaboration with Qualcomm, whose Qualcomm Life subsidiary provides wireless solutions for the management of chronic diseases and sharing of medical information. ... Novartis plans a 2019

• Novartis' combo COPD inhaler cleared in EU

  Becomes first dual action bronchodilator approved in EU for COPD. Novartis' Ultibro Breezhaler has become the first dual action bronchodilator to be approved in the EU for chronic obstructive pulmonary disease ... Many COPD patients will now have a

• Boehringer’s first cancer drug leads EMA recommendations

  Novartis COPD inhaler recommended in EU. Elsewhere among the CHMP's recommendations, Novartis received backing for the Ultibro Breezhaler as a once-daily maintenance treatment to relive symptoms in adults with ... The product, which is to be marketed as